Medical Oncology

, Volume 29, Issue 5, pp 3176–3182

Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer

Authors

  • Georg Holgersson
    • Section of Oncology, Department of Radiology, Oncology and Radiation SciencesUppsala University
    • Department of Medical Sciences, Respiratory MedicineUppsala University
  • Even Hoye
    • Department of OncologyGävle Hospital
  • Stefan Bergström
    • Department of OncologyGävle Hospital
  • Roger Henriksson
    • Department of OncologyUmeå University Hospital
  • Simon Ekman
    • Section of Oncology, Department of Radiology, Oncology and Radiation SciencesUppsala University
  • Jan Nyman
    • Department of OncologySahlgrenska University Hospital
  • Martin Helsing
    • Department of OncologySkåne University Hospital
  • Signe Friesland
    • Karolinska University Hospital
  • Margareta Holgersson
    • Section of Oncology, Department of Radiology, Oncology and Radiation SciencesUppsala University
  • Kristina Lamberg Lundström
    • Department of Medical Sciences, Respiratory MedicineUppsala University
  • Christer Janson
    • Department of Medical Sciences, Respiratory MedicineUppsala University
  • Elisabet Birath
    • Department of OncologySkåne University Hospital
  • Charlotte Mörth
    • Section of Oncology, Department of Radiology, Oncology and Radiation SciencesUppsala University
  • Thomas Blystad
    • Department of General OncologyLinköping University Hospital
  • Sven-Börje Ewers
    • Department of OncologyLund University Hospital
  • Britta Löden
    • Department of OncologyCentral Hospital
  • Michael Bergqvist
    • Section of Oncology, Department of Radiology, Oncology and Radiation SciencesUppsala University
Original Paper

DOI: 10.1007/s12032-012-0247-3

Cite this article as:
Holgersson, G., Sandelin, M., Hoye, E. et al. Med Oncol (2012) 29: 3176. doi:10.1007/s12032-012-0247-3

Abstract

There is a need to improve the prognostic and predictive indicators in non-small cell lung cancer (NSCLC). At present, the main focus is on genetic predictive markers while the prognostic value of the standard blood variables related to haematopoiesis has been subjected to relatively limited attention. To study the prognostic potential of haemoglobin (Hgb), platelet (Plt) and white blood cell (WBC) levels at time of diagnosis in NSCLC patients, 835 NSCLC patients, stage I-IV, who received radiotherapy with curative intention (>50 Gy), were included in the study. WBC, Plt, Hgb, gender, age at diagnosis, stage, surgery and first-line chemotherapy were studied in relation to overall survival. For patients with Hgb < 110 g/L and Hgb ≥ 110 g/L), the median survival was 11.2 and 14.5 months, respectively (p = 0.0032). For WBC > 9.0 × 109/L and < 9.0 × 109/L, the median survival was 11.6 and 15.4 months, respectively (p < 0.0001). For Plt > 350 × 109/L and <350 × 109/L, the median survival was 11.2 and 14.9 months, respectively (p < 0.0001). The median survival in patients with pathological results in all three markers was half of that in patients with normal levels of all three markers (8.0 and 16.0 months, respectively (p < 0.0001). The level of the three studied haematological biomarkers corresponds significantly to outcome in NSCLC. These results indicate that standard haematological variables may be used as guidance for the clinician in the decision-making regarding treatment intensity and patient information.

Keywords

Non-small cell lung cancerPrognosisBiomarkerAnaemiaThrombocytosisLeukocytosis

Supplementary material

12032_2012_247_MOESM1_ESM.pdf (83 kb)
Online resource 1: Patient characteristics, treatment, relapse and cause of death (PDF 83 kb)
12032_2012_247_MOESM2_ESM.pdf (56 kb)
Online Resource 2: Estimated median survival and 5-year survival rate for patients with different lab risk factors (PDF 55 kb)

Copyright information

© Springer Science+Business Media, LLC 2012